OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

HTML

Year: 2006
Type: article
Study design: Clinical Trial
Source: Investigational New Drugs
DOI: 10.1007/s10637-006-9014-7
Authors: Richard Kefford, Jane McNeil Beith, Guy Arthur Van Hazel, Michael Millward, James Marshall Trotter, David Keith Wyld, Rada Kusic, Revati Shreeniwas, Adele Morganti, Andrea Ballmer, Eleonor Segal, Oliver Nayler, Martine Clozel
Institutions: The University of Sydney, Westmead Hospital, Actelion (Switzerland), Royal Prince Alfred Hospital, Royal Perth Hospital, Royal Brisbane and Women's Hospital, Westmead Institute
Language: English

Topic: Cutaneous Melanoma Detection and Management
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: bosentan, endothelin receptor antagonists, metastatic melanoma, stage IV melanoma, monotherapy, stable disease, tumor response, RECIST, adverse events, liver function, anticancer activity
SDG: Good health and well-being

Open Access status: closed

Funder: Actelion Pharmaceuticals
OpenAlex ID: W1985669197
FWCI: 2.993
Cites: 24
Cited by: 67
Related to: 8
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security